![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The majority of Monsanto's pharmaceutical patents are filed in the name of Searle, and virtually all originate in the US. Following a period of decline, the level of patenting is now increasing sharply, so that the number of publications in 1996 is projected to exceed 100, including several exceptionally long and detailed new compound inventions. Neurologicals and antivirals form the nucleus of Monsanto's patenting; various musculoskeletal projects are growing in importance, at the same time as cardiovasculars and antithrombotics decline. A sharply focused patenting policy results in applications being filed either in the US only, or in the maximum number of countries available via the PCT, there being roughly equal numbers of inventions in these two extreme categories.